Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

In Vitro Maturation: Maturing Immature Eggs Outside of the Ovaries Offers A Successful Fertility Option for Many

Dr. Ralf Zimmermann with Neway Fertility with Tips on why IVM is a safer technique for women with ovarian disorders.


News provided by

Neway Fertility

Oct 04, 2018, 09:00 ET

Share this article

Share toX

Share this article

Share toX

Dr. Ralf Zimmermann
Dr. Ralf Zimmermann

NEW YORK, Oct. 4, 2018 /PRNewswire-PRWeb/ -- Increasing success with the way eggs are matured outside a person's ovaries has given new hope to women who have difficulty becoming pregnant, especially those with diseases or disorders that make use of conventional in vitro fertilization techniques less effective – or even risky.

So, states Ralf Zimmermann MD, reproductive endocrinologist and infertility specialist and medical director of Neway Fertility in New York City, who says the improved fertility process -- in vitro maturation (IVM) – is becoming the technique of choice for promoting pregnancy in patients with conditions like polycystic ovarian syndrome, a common hormonal disorder, or in women with cancer or with limited eggs, often due to advanced age.

Research also has demonstrated IVM’s success in preserving healthy oocytes – immature ovum or egg cells – harvested from women facing cancer treatments that are likely to make them infertile.

Post this

"Research also has demonstrated IVM's success in preserving healthy oocytes – immature ovum or egg cells – harvested from women facing cancer treatments that are likely to make them infertile," explains Dr. Zimmermann,

He cites comments made in 2017 by authors of a report in the journal, Reproductive Medicine and Biology, that improved cancer survival rates are increasing demand for fertility preservation. An estimated 20 percent of gynecologic cancers occur in women of reproductive age. Survivors of these cancers often undergo radiation and chemotherapy regimens that affect ovarian function.

Unlike in vitro fertilization in which a woman is directly given medications to stimulate egg production and maturation inside her ovaries, IVM involves harvesting immature eggs without stimulating the ovaries – or only minimally stimulating them – and then maturing the eggs in a laboratory using a protein-rich culture medium and small amounts of hormones, Dr. Zimmermann explains.

Once matured, the eggs are fertilized through intracytoplasmic sperm injection, in which one sperm is injected into each egg with a small needle. The resulting embryos can then be transferred immediately to the uterus or preserved through a freezing technique called vitrification, or "flash freezing", and introduced to the uterus later when a woman is ready to become pregnant.

"IVM is an important fertility alternative for women with polycystic ovarian syndrome because these patients are prone to developing ovarian hyperstimulation syndrome (OHSS) when exposed to the drugs used in traditional in vitro fertilization," says Dr. Zimmermann. OHSS occurs when fluid from the ovary shifts to other parts of the body, including abdomen and lungs. It is a common complication of fertility treatment and can develop into a serious – even fatal – disorder.

For women recovering from cancer, conventional in vitro fertilization drugs used to stimulate the ovaries may contain hormonal components that also stimulate any remaining cancer tissue in the body. "That's why IVM can be a more acceptable fertility approach for these patients," Dr. Zimmermann says.

Others who may benefit from IVM include women with limited remaining eggs and those who have blocked or removed fallopian tubes or suffer from ovulation problems or autoimmune diseases.

Besides the enhanced safety that IVM affords women with various disorders, the technique is oftentimes more convenient than in vitro fertilization and can be performed at lower cost.

Dr. Zimmermann concurs with researchers who say IVM still has "a long way to go," but says the technique continues to advance at an amazing rate. In fact, authors of a study published in August 2018 in the Journal of Ovarian Research report that, in women of reproductive age who have polycystic ovarian syndrome, IVM is proving to be a "convenient option" with a live birth rate like that of standard in vitro fertilization.

"Ongoing advancements in IVM techniques are leading to more successful outcomes," Dr. Zimmermann says. "As we learn more in our clinical practice, we will be better able to select patients who can achieve the highest results from IVM."

Bio: Dr. Ralf Zimmermann is dual board-certified in OB/GYN and Reproductive Endocrinology/Infertility. As Neway Fertility's Medical Director and fertility specialist, Dr. Ralf Zimmermann comes from an accomplished background in reproductive endocrinology and assisted reproductive technologies (ART), with a special interest in the psychological factors of infertility treatment. http://www.newayfertility.com

SOURCE Neway Fertility

Related Links

http://www.newayfertility.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.